Herramientas de usuario
sars-cov-2_elicits_robust_adaptive_immune_responses_regardless_of_disease_severity_-_ebiomedicine_thelancet.com
Administrador de Ficheros
Espacios de nombres
Escoge "espacio de nombre"
Archivos Multimedia
Ficheros en [root]
- acute_severe_ulcerative_colitis_after_mrna_coronavirus_disease_2019_vaccination.png
- 958×275
- 2023/04/28 19:25
- 24.8 KB
- addressing_anti-syncytin_antibody_levels_and_fertility_and_breastfeeding_concern.png
- 1101×269
- 2023/08/02 18:21
- 23.7 KB
- addressing_anti-syncytin_antibody_levels_and_fertility_and_breastfeeding_concerns_.pdf
- 2023/08/02 18:24
- 1.3 MB
- apparent_risks_of_pots_postural_orthostatic_tachycardia_syndrome_diagnoses_after_covid-19_vaccination_and_sars-cov-2_infection.png
- 759×291
- 2023/04/28 19:25
- 43.3 KB
- assessment_of_myocardial_18f-fdg_uptake_at_pet_ct_in_asymptomatic_sars-cov-2_vaccinated1.png
- 1280×720
- 2023/11/03 11:22
- 403.8 KB
- constructive_and_obsessive_criticism_in_science_1_.pdf
- 2023/04/28 19:25
- 125.1 KB
- covid-19_vaccination-related_small_vessel_vasculitis_with_multiorgan_involvement.png
- 931×280
- 2023/09/15 19:11
- 23 KB
- covid-19_vaccination_uptake_in_europe_and_2022_excess_all-cause_mortality.png
- 986×198
- 2023/04/28 19:26
- 28.3 KB
- cross-reactive_memory_t_cells_associate_with_protection_against_sars-cov-2_infection_in_covid-19_contacts..png
- 500×205
- 2023/04/28 19:26
- 21.7 KB
- crucero.png
- 1200×746
- 2023/04/28 19:26
- 1.2 MB
- effectiveness_of_the_coronavirus_disease_2019_covid-19_bivalent_vaccine.png
- 708×348
- 2023/04/28 19:26
- 28 KB
- effects_of_vaccination_and_previous_infection_on_omicron_infections_in_children.pdf
- 2024/02/29 18:51
- 606.5 KB
- eur_j_clin_investigation_-_2022_-_ioannidis_-_the_end_of_the_covid‐19_pandemic.pdf
- 2023/04/28 19:26
- 406.9 KB
- exceso_moralidad_europa_2.png
- 1108×842
- 2023/04/28 19:26
- 59.1 KB
- exceso_moralidad_europa_3.png
- 1108×842
- 2023/04/28 19:26
- 62.1 KB
- foto_de_vacunacion_-_copia.jpg
- 517×235
- 2023/04/28 19:26
- 12.4 KB
- increased_age-adjusted_cancer_mortality_after_the_third_mrna-lipid_nanoparticle_vaccine_dose.png
- 758×450
- 2024/04/16 19:39
- 48.5 KB
- is_there_a_link_between_the_2021_covid-19_vaccination_uptake.pdf
- 2023/04/28 19:26
- 455.1 KB
- logo.png
- 776×125
- 2023/04/28 19:26
- 126.4 KB
- muertes_tras_la_injecciones_vacunales_uk.png
- 843×527
- 2023/04/28 19:26
- 190.8 KB
- new-onset_giant_cell_arteritis_following_covid-19_mrna_vaccine.png
- 1325×271
- 2023/04/28 19:26
- 149.4 KB
- past_sars-cov-2_infection_protection_against_re-infection.pdf
- 2023/04/28 19:26
- 1.1 MB
- past_sars-cov-2_infection_protection_against_re-infection_a_systematic_review_and_meta-analysis.png
- 958×292
- 2023/04/28 19:26
- 159.6 KB
- potential_health_risks_of_mrna-based_vaccine_therapy_a_hypothesis.png
- 828×274
- 2023/04/28 19:26
- 17.4 KB
- risk_of_infection_hospitalisation_and_death_up_to_9_months_after_a_second_dose_of_covid-19_vaccine.png
- 738×194
- 2023/04/28 19:26
- 28.1 KB
- risk_of_sars-cov-2_acquisition_and_preferred_mask_type.png
- 737×231
- 2023/04/28 19:26
- 19.2 KB
- sars-cov_2_biologia_y_estructura..pdf
- 2023/04/28 19:26
- 1.6 MB
- severe_covid-19_outcomes_after_full_vaccination_of_primaryschedule_and_initial_boosters_pooled_analysis.png
- 922×257
- 2023/04/28 19:26
- 82.6 KB
- the_incidence_of_myocarditis_and_pericarditis_in_post_covid-19_unvaccinated_patients.png
- 798×251
- 2023/04/28 19:26
- 20.6 KB
- the_new_crisis_of_increasing_all-cause_mortality_in_us_children_and_adolescents.pdf
- 2023/04/28 19:26
- 123.1 KB
- ulcerative_colitis_flare-ups_following_mrna_covid-19_vaccination.png
- 705×675
- 2023/04/28 19:26
- 135.8 KB
- update_on_covid-19_pandemic_event.pdf
- 2023/04/28 19:26
- 286.9 KB
Fichero
- Ver
- Historial
- Fecha:
- 2023/04/28 19:26
- Nombre del archivo:
- past_sars-cov-2_infection_protection_against_re-infection.pdf
- Tamaño:
- 1MB
- Referencias para:
- respuesta_inmunitaria
- start
Herramientas de la página
Excepto donde se indique lo contrario, el contenido de este wiki esta bajo la siguiente licencia: CC Attribution-Share Alike 4.0 International
